An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.

ABSTRACT:

Aim

Fenofibrate, a PPAR-α inhibitor used for treating dyslipidemia, has well-documented anti-inflammatory effects that vary between individuals. While DNA sequence variation explains some of the observed variability in response, epigenetic patterns present another promising avenue of inquiry due to the biological links between the PPAR-α pathway, homocysteine and S-adenosylmethionine - a source of methyl groups for the DNA methylation reaction.

Hypothesis

DNA methylation variation at baseline is associated with the inflammatory response to a short-term fenofibrate treatment.

Methods

We have conducted the first epigenome-wide study of inflammatory response to daily treatment with 160 mg of micronized fenofibrate over a 3-week period in the Genetics of Lipid Lowering Dr

SUBMITTER: Yusuf N 

PROVIDER: S-EPMC5593083 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature